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TLRPattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), contribute to the development of in-
testinal inﬂammatory diseases, like inﬂammatory bowel disease (IBD). Supporting investigations of the un-
derlying mechanisms of IBD, this study provides an extensive PRR expression survey together with T-cell
associated factors along the murine colon during experimental colitis. 8–12 week-old C57BL/6 mice were
treated with dextran sodium sulfate (DSS) to induce colitis. The mRNA expression levels of Tlr1–9, Nod1,
Nod2, T cell subset-associated master transcription factors and cytokines were determined using qPCR. The
expression of TLR2, 4, 5 and 6 was determined with immunohistochemistry. Th1 and Th17 associated re-
sponses were quantiﬁed in the mesenteric lymph nodes (mLNs) using ﬂow cytometry. In DSS treated mice,
the mRNA expression of the majority of PRRs was increased relative to healthy controls and correlated
with the degree of inﬂammation. The exceptions were Tlr1 and Tlr5, which displayed unchanged and
down-regulated transcription, respectively. Furthermore, in healthy animals, there was increased transcrip-
tion of Tlr2, 3 and 5 near the caecum as opposed the region near the rectum. Within the inﬂamed regions, the
mRNA expression of Th1-, Th17- and regulatory T-cell associated cytokines was enhanced, while there was
no change for Th2-associated cytokines. In agreement with the mRNA expression, enhanced IFNγ and
IL-17 producing cells were observed in stimulated mLNs. This study provides an extensive expression survey
of PRRs along the colon during the acute colitis and shows that the induced inﬂammation is characterized by
a Th1- and IL-17 mediated cytokine response.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Over the last decade, the incidence rate of IBD and especially
Crohn's disease (CD) has increased [1]. Currently, there is still no cu-
rative therapy for IBD and the treatments that do exist focus mainly
on relieving symptoms and often lead to unwanted side effects [2].
Due to the need for improved medications that target more than
just symptoms, there is a growing interest in targeting receptors
that may modulate IBD initiation and/or progression, such as PRRs [3].
PRRs are expressed by a broad range of immune cells. They are
able to recognize pathogen-associated molecular patterns (PAMPs),
molecules that are unique to bacteria, fungi, parasites, and viruses;, Utrecht Institute for Pharma-
O box 80082, 3586CG Utrecht,
537900.
d).
l rights reserved.and their stimulation leads to the initiation of immune defense mech-
anisms. Studies using germ-free animals and observations from pa-
tients undergoing fecal-stream diversion have demonstrated that
the development and maintenance of colitis are strongly associated
with the presence of intestinal ﬂora. Given the requirement of bacte-
ria for the initiation of intestinal inﬂammation, PRRs may be impor-
tant for the development and, possibly, the chronic nature of IBD,
and therefore serve as a potential target for future treatments.
Toll-like receptors (TLRs) and nucleotide-binding oligomerization
domain-containing proteins (human: NOD, mouse: Nod) of the Nod-
like receptor family are two important groups of PRRs. To date, 13
TLRs are known, of which TLR1–9 are conserved in both humans
and mice. TLRs can be located both extracellularly and intracellularly
[4]. They are able to provide protection against a broad range of
pathogens by recognizing speciﬁc PAMPs, such as bacterial cell wall
components (TLR2, TLR4 and TLR5), bacterial-derived DNA (TLR9),
and virus-derived RNA (TLR3, 7 and 8). TLR1 and TLR6 both pair
with TLR2 to form heterodimers that recognize triacyl- and diacyl-
lipopeptides from bacteria, respectively [5].
The NOD/Nod proteins are localized exclusively within the cytosol
and are able to detect peptidoglycans, components on the bacterial
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was directly linked to the development of IBD, especially CD [6]. A
c-terminal variant of Nod2 results in reduced downstream NF-κB
activation after stimulation [7,8]. Polymorphisms of Tlrs are also
associated with the susceptibility of IBD development, such as
the Asp299GLy polymorphism of Tlr4, which results in a deﬁcient Li-
popolysaccharide (LPS) response and polymorphisms of Tlr1, 2 and 6
[9,10]. In addition to genetic associations, clinical studies have shown
enhanced expression of TLRs including TLR2, TLR3, TLR4 and TLR8 in
the inﬂamed colonic tissue of IBD patients [3,11–13].
Experimental colitis in mice has been used to help elucidate the
role of PRRs in the development of IBD. Among mouse models of co-
litis, the DSS-induced colitis is by far the most commonly used due to
its simplicity and its ability to induce a predictable inﬂammation in
the colon [14,15]. Though, DSS colitis was ﬁrst considered an ulcera-
tive colitis model with type 2 T-helper (Th2) skewing, gene scans
[16] and additional research have shown that the acute DSS model in-
duces many genes associated with CD, including type 1 T-helper cell
(Th1) and T-helper 17 (Th17) associated cytokine expression [17–20].
Studies using the DSS colitis model in TLR−/− mice have shown
that TLRs have the capacity to inﬂuence colitis development. Both
TLR4−/− and TLR2−/− mice experience a more severe colitis than
control mice [21–23] while TLR9−/− mice are reported to have
reduced symptoms [24]. Treatment of acute DSS colitis with TLR li-
gands have shown varying effects which appear to be highly depen-
dent on the mode of administration. The effects include protective
effects with the TLR3 ligand, poly I:C [25] and the TLR1/2 ligand,
PAM3Cys-SK4 [23] and ambiguous effects with the TLR9 ligand, CpG
DNA [24,26] and the TLR5 ligand, ﬂagellin [27,28].
Despite the major role PRRs could play in IBD development and
progression, the underlying mechanisms remain unknown. It is fur-
ther complicated by the fact that PRRs, on the one hand, are known
to stimulate the immune response, yet on the other hand, often
have a protective role in in vivo models of colitis by maintaining the
barrier function of the intestinal epithelial cell layer [21–23,25]. In
order to help decipher the precise role of PRRs in colitis, we have pro-
vided an extended overview of the transcriptional modulation of
Tlr1–9, Nod1 and Nod2 along the colon during DSS-induced colitis.
We have also determined the location of expression for TLR2, 4, 5
and 6 in the colon with immunohistochemistry. Furthermore, we
have simultaneously assessed the mRNA expression of cytokines and
transcription factors representing different T-helper cell populations.
2. Materials and methods
2.1. Animals
Female C57BL/6 mice were purchased from Charles River Laborato-
ries (Maastricht, The Netherlands). All mice were used at 8–12 weeks
of age andwere housed under standard conditions in the animal facilities
at Utrecht University. All animal experiments were approved by and
were in accordance with the guidelines of the Dutch Experimental Ani-
mal Commission. The approval document is encodedwith 2008.II.03.030.
2.2. Experimental colitis
Experimental colitis was induced in groups of 9 mice by adding
1.5% DSS to the drinking water of the mice for 6 days. The weight
was measured every day until the end of the experiment. Mice were
sacriﬁced on day 7 and colitis was evaluated according clinical and
histological parameters. The clinical features of colitis were deter-
mined by using the data collected from the weight measurement,
feces condition and the weight/length ratio of the isolated colons.
The feces condition score was determined from two parameters: stool
consistency (0 = normal, 1 = soft with normal form, and 2 = loss of
form/diarrhea) and fecal bleeding (0 = noblood, 1 = blood observationusing Colo-rectal Test kit (Axon Lab AG, Germany), and 2 = blood obser-
vation without test).
After sacriﬁcing the mice, the colons were excised between the
ileocaecal junction and rectum and were prepared for histological
evaluation. The colon was opened longitudinally, placed on a piece
of blotting paper, and ﬁxed in 10% formalin. After ﬁxing, the colons
were rolled, parafﬁn-embedded, and sectioned (5 μm). Two researchers
assessed general inﬂammatory features blindly after staining sections
with hematoxylin and eosin according the assessment system described
below. Individual scores were tallied for the proximal colon (character-
ized by bulges in the colonwall) and the distal colon (the region starting
from end of proximal portion stretching to the anus). Assessments
included four pathological criteria: the extent of cellular inﬁltration
(0: no inﬁltration, 1: inﬁltration between the crypts, 2: inﬁltration in
the submucosa, 3: inﬁltration in the muscularis externa, and 4: inﬁltra-
tion in entire tissue); cover area of cellular inﬁltration in the region
(0: no inﬁltration, 1: b25%, 2: 25%–50%, 3: 50%–75%, and 4: N75%);
loss of crypts (0: no damage, 1: 30% shortening of crypts, 2: 65% shorting
of crypts, 3: total loss of crypts, and 4: loss of entire epithelial layer); ex-
tent of crypts loss in the region (0: no crypt loss, 1:b25%, 2: 25%– 50%, 3:
50%–75%, 4:N75%). Ly-6B+cell inﬁltrationwas considered an additional
indicator for colitis and stains primarily neutrophils and macrophages.
The Ly-6B staining is described in Section 2.3, “Immunohistochemical
staining”.2.3. Immunohistochemical staining
For immunohistochemical staining, 5-μm-thick sections were sub-
jected to a heat-induced epitope retrieval step. Slides were washed
with 1× phosphate buffered saline (PBS) buffer and blockedwith rabbit
or goat serum, before an overnight incubation at 4 °C with primary an-
tibodies against Ly-6B (MCA771GA, AbD Serotec, Dusseldorf, Germany),
TLR2 (ab24192, Abcam, Cambridge, UK), TLR4 (ab47093, Abcam,
Cambridge, UK), TLR5 (ab62460, Abcam, Cambridge, UK) and TLR6
(SAB1300202, Sigma, UK). For detection, biotinylated goat anti-rat
(E0468, Dako, Glostrup, DK) and goat anti-rabbit (E0432, Dako,
Glostrup, DK) secondary antibodies were administered followed by in-
cubation with peroxidase-labeled streptavidin (Vectastain Elite ABC
kit, PK-6200, Vector, Burlingame, CA USA). The peroxidase activity
was visualized using DAB (D5637, Sigma, UK). Background staining
was determined by substituting the primary antibody with the rele-
vant isotype control, either rat (ab37261, Abcam, Cambridge, UK) or
rabbit (ab27472, Abcam, Cambridge, UK) IgG antibody.2.4. mRNA expression analysis
The colons were divided into four equal sections: proximal (P),
medial 1 (M1), medial 2 (M2) and distal (D). The total RNA was iso-
lated using the RNAeasy kit (Qiagen, Germantown, MD, USA) and,
subsequently, reverse transcribed into cDNA using the iScript cDNA
synthesis kit (BioRad, Hercules, CA, USA). Real-time PCR was per-
formed using iQ SYBR Green supermix kit (Bio-Rad, Hercules, CA
USA) with the CFX 96 Real-time system (BioRad, Hercules, CA USA)
and the relative mRNA expression values were calculated using
Bio-Rad CFX manager V1.6. The sequence of speciﬁc primers for
Nod1 and Nod2, Tlrs, T cell transcription factor genes, and the gene
for the household protein ribosomal protein S13 (Rps13) are listed
in Table 1. The primers for the cytokines: tumor necrosis factor-α
(Tnf), interferon-γ (Ifn-gamma), interleukin-1β (Il-1beta), Il-6, mono-
cyte chemotactic protein-1 (Ccl-2), Il-4, Il-6, Il-10, Il-12p35, Il-17,
Il-23p19 and transforming growth factor β (Tgf-beta) were pur-
chased from SABioscience (Frederick, MD, USA). The ﬁnal data for
the target samples were normalized against the internal control
Rps13.
Table 1
qPCR primer sequences for PPRs, T cell transcription factors and RPS13.
Primer sequence 5′ → 3′
Forward primer Reverse primer
Tlr1 GGTGTTAGGAGATGCTTATGGGG GATGTTAGACAGTTCCAAACCGA
Tlr2 CCAGACACTGGGGGTAACATC CGGATCGACTTTAGACTTTGGG
Tlr3 GGGGTCCAACTGGAGAACCT CCGGGGAGAACTCTTTAAGTGG
Tlr4 GCCTTTCAGGGAATTAAGCTCC AGATCAACCGATGGACGTGTAA
Tlr5 TCAGACGGCAGGATAGCCTTT AATGGTCAAGTTAGCATACTGGG
Tlr6 GACTCTCCCACAACAGGATACG TCAGGTTGCCAAATTCCTTACAC
Tlr7 TCTTACCCTTACCATCAACCACA CCCCAGTAGAACAGGTACACA
Tlr8 GGCACAACTCCCTTGTGATT CATTTGGGTGCTGTTGTTTG
Tlr9 ACTCCGACTTCGTCCACCT GGCTCAATGGTCATGTGGCA
Nod1 GAAGGCACCCCATTGGGTT AATCTCTGCATCTTCGGCTGA
Nod2 CCGCTTTCTACTTGGCTGTC GTGATTTGCAGGTTGTGTGG
Tbet GCCAGCCAAACAGAGAAGAC AAATGTGCACCCTTCAAACC
Gata3 GCGGTACCTGTCTTTTTCGT CACACAGGGGCTAACAGTCA
Foxp3 CACTGGGCTTCTGGGTATGT AGACAGGCCAGGGGATAGTT
Rorc-γt TGCAAGACTCATCGACAAGG AGGGGATTCAACATCAGTGC
Rps13 GTCCGAAAGCACCTTGAGAG AGCAGAGGCTGTGGATGACT
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Mice were treated with DSS or water for 6 days and on day 7 the
mice were sacriﬁced. After sacriﬁcing the mice, the mesenteric
lymph nodes were isolated and prepared as single-cell suspensions.
All reagents and antibodies used were obtained from eBioscience
(San Diego, CA, USA). Brieﬂy, 105 cells were transferred to 96 well
round bottom plates and activated by incubating at 37 °C for 24 h in
wells coated with anti-CD3. After stimulation, cells were incubated
for 4 h with Brefeldin A. Before staining, Fc-receptors were blocked
using CD16/Cd32 to prevent non-speciﬁc binding of antibody. TheFig. 1. DSS treatment induces colitis in mice. C57BL/6 mice have received either normal
change of mice over time. (B) Fecal condition of healthy mice (control) or DSS-treated mi
day 7, the mice were sacriﬁced and the ratio of colon length over weight was determined
* p b 0.05; *** p b 0.001. (D) Histological quantiﬁcation of inﬂammatory markers was deter
tiﬁcation parameters are described in experimental procedures. Results are expressed as m
either healthy mice or DSS-treated mice. Both proximal (P) and distal (D) colon regions arcells were stained extracellularly with antibodies for CD4. Subse-
quently, the cells were ﬁxed and permeabilized using the Foxp3 intra-
cellular staining buffer set and stained with anti-IL-17A PE and
anti-IFNγ PerCP-Cy5.5. The samples were read on a BD FACSCanto II
(BD Biosciences, Franklin Lakes, NJ, USA). Intracellular cytokine stain-
ing was analyzed using BD FACSDiva software (BD Biosciences).
2.6. Statistical analysis
Means with SEM are represented in each graph. Statistical analysis
was performed using GraphPad Prism version 5.0 for windows
(GraphPad Software, San Diego, CA USA). p-Values were calculated
using the Mann–Whitney test. p-Values considered as signiﬁcant
are indicated as *** b0.001, **b0.01, and *b0.05.
3. Results
3.1. Colitis severity during DSS treatment
Experimental colitis in C57BL/6 mice was induced by adding 1.5%
DSS to the drinking water for six days. As expected, weight loss and
diarrhea with blood were observed only in the treated group
(Fig. 1A and B). The colon length and weight ratio was signiﬁcantly
decreased in the DSS-treated mice as shown in Fig. 1C indicating se-
vere inﬂammation.
To determine the extent of inﬂammation at the proximal and dis-
tal ends of the colon, the colons were ﬁxed and stained with hema-
toxylin and eosin and scored for disease severity. DSS-treated mice
displayed extensive signs of inﬂammation as compared to healthy
mice (Fig. 1D). The damage was predominantly found in the distaldrinking water or drinking water with 1.5% DSS for 6 days. (A) Percent body weight
ce (DSS) was determined by measuring diarrhea and blood in feces on day 6. (C) On
in individual colons. Results are expressed as mean ± SEM for n = 9 mice per group,
mined within colons derived from both healthy mice and DSS-treated mice. The quan-
ean ± SEM for n = 3 mice per group, *** p b 0.001. (E) H&E staining of colons from
e shown. The photos are representative for n = 3 mice per group.
Fig. 2.Massive Ly-6B+ cell inﬂux in the distal colon region of DSS-treated mice. The colon was divided into proximal and distal regions according to the morphological character-
istics described in experimental procedures and assessed for the presence of Ly-6B+ cells, which are mainly neutrophils and inﬂammatory macrophages. Immunohistochemical
staining was used to visualize Ly-6B+ cells at the proximal and distal colon region of healthy mice (A) and of DSS-treated mice (B). An example of a positively stained cell is in-
dicated with the arrow. The pictures are representative of n = 3 mice per group.
2165B. Zheng et al. / Biochimica et Biophysica Acta 1832 (2013) 2162–2172region of the colon and included complete loss of crypt structure. The
proximal region, in contrast, remained generally unscathed. Submu-
cosal inﬂammatory cell inﬁltration was observed in 50–70% area of
the whole colon, most prominently in distal (D) areas when com-
pared to the proximal part of the colon (Fig. 1E). Immunohistochem-
istry was employed to determine the extent of inﬁltrated cells
expressing Ly-6B, which exhibits particularly high expression on the
surface of neutrophils and inﬂammatory macrophages. The regional
tissue damage was mirrored by the immune cell inﬂux measured by
Ly-6B, which was mainly constrained to the distal regions of the colon
in DSS-treated mice and not found in the control mice (Fig. 2A and B).
Thus, the inﬂammation detected in the colon of our DSS-treated mice
conformed to the generally accepted pathology of DSS-induced colitis.
3.2. mRNA expression levels of Nod1 and Nod2 are increased during DSS
colitis
To determine the mRNA expression of Nod1 and Nod2 during DSS
colitis, we investigated speciﬁc mRNA expression along the length of
the colons isolated from both healthy mice and mice suffering from
DSS-induced colitis (Fig. 3A). The mRNA transcripts of both Nod1
and Nod2 were up-regulated within the inﬂamed distal region of
the colon. In the non-inﬂamed proximal region, there was no
up-regulation of the mRNA encoding Nod1 and Nod2 (Fig. 3B) demon-
strating that up-regulated expression correlates with the presence of
gross inﬂammation.
3.3. mRNA encoding TLRs that recognize bacterial PAMPs are differential-
ly modulated in DSS colitis
The main crux of this survey was to assess the mRNA expression of
the conserved Tlr1–9 along the length of the colon in both healthymice and diseased mice. Of particular interest are the TLRs that recog-
nize bacterial-associated PAMPs as it is known that intestinal inﬂam-
mation relies on the presence of intestinal bacteria. The mRNA
expression of bacterial-associated Tlrs (Tlr1, 2, 4, 5, 6, and 9) is
shown in Fig. 3C. In healthy mice, the mRNA expression of these Tlrs
is stabilized along the length of the colon, with exception of Tlr2
and Tlr5, which had a higher expression in the proximal colon region.
In DSS-treated mice, Tlr2, 4, 6 and 9 expression levels were up-
regulated in the inﬂamed colon region. TLR1 and TLR6 both pair
with TLR2 to form functional heterodimers and discriminate triacyl-
and diacyl-lipopeptide, respectively [29]. Though both Tlr2 and Tlr6
were up-regulated within the inﬂamed region of the colon, Tlr1
displayed no enhanced expression. Interestingly, TLR5, which recog-
nizes ﬂagellin, was observed to have a decreased mRNA expression
within the inﬂamed distal region of the colon.3.4. Colitis leads to the up-regulation of TLR transcripts that are associated
with virus detection
TLR3 and TLR7/8 are known to provide protection against viral
infection, recognizing double-stranded RNA (dsRNA) and single-
stranded RNA (ssRNA), respectively [30–32]. In order to determine
the effects of inﬂammation on the expression of the virus-associated
TLRs, we analyzed their mRNA expression along the length of colons
obtained from both DSS-treated and healthy mice (Fig. 3D). The
mRNA expression pattern of Tlr3 detected in the colon was similar
in both DSS-treated mice and healthy mice; although a marginal in-
crease was observed in the inﬂamed colon region of DSS-treated ani-
mals. In contrast to Tlr3, large increases of mRNA expression were
seen for both Tlr7 and Tlr8 within the inﬂamed regions as compared
to control colon samples.
Fig. 3. The mRNA expression of PRRs is differentially modulated in the colons of DSS-treated mice. A) Photo of colon illustrating the four regions that were examined: P = proximal
region, M1 = proximal middle region, M2 = distal middle region, D = distal region. mRNA expression of NOD proteins (B), bacterial-associated Tlrs: Tlr4, Tlr9, Tlr2, Tlr6, Tlr1 and
Tlr5 (C) and virus-associated Tlrs: Tlr3, Tlr7 and Tlr8 (D) were examined in four different colon regions using qPCR. Results are expressed as mean ± SEM, n = 6 mice per group,
pooled from two independent experiments, * p b 0.05; ** p b 0.01; *** p b 0.001.
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We assessed the expression of several bacterial-associated TLR
molecules (TLR2, 4, 5, and 6) in the colons of both healthy and
DSS-treated mice using immunohistochemical staining. TLR4 positive
cells were found throughout the colon in both healthy and DSS-
treated mice. TLR4 was frequently found expressed in the epithelial
layer found at the base of the crypts in the distal colon of both healthy
and DSS-treated mice (Fig. 4A).
TLR2 was expressed along the length of colons in cells in the epi-
thelial layer and lamina propria (Fig. 4B) of both healthy and DSS
treated mice. In contrast to TLR2 and TLR4, the heterodimer partner
of TLR2, TLR6, was detected only in the epithelial layer of colons de-
rived from DSS-treated mice (Fig. 4C). The TLR6 positive cells were
found at both the proximal and distal areas, clustered in patches. Un-
like TLR2, 4 and 6, TLR5 staining was clearly found on mononuclear
cells within the lamina propria as well in the epithelial cell layer
(Fig. 4D) in both healthy and inﬂamed colons.3.6. Colitis leads to modulations in the mRNA expression of T cell-
associated master transcription factors
Histological analysis of our DSS-treated mice displayed both exten-
sive damage and inﬂammatory monocyte inﬁltration within the distal
region of the colon congruent with DSS colitis characteristics already
published. However, clinical observations add limited information
about the type of adaptive immune response present locally within
the tissue (Th1, Th2, Treg or Th17). Next, we measured the mRNA
expression of the transcription factors, T-bet (Tbet), GATA-3 (Gata3),
Foxp-3 (Foxp3) and RORγt (Rorc), which are associated with Th1 cells,
Th2 cells, regulatory T cells (Treg cells) and Th17 cells, respectively
(Fig. 5) [20]. Similar to the Tlr expression patterns, the mRNA of the
Th1-associated transcription factor Tbet was increased in the distal re-
gion (Fig. 5A). In the same region, Gata3 and Foxp3were also moderate-
ly increased (Fig. 5B and C). Interestingly, the mRNA expression of Rorc,
the transcription factor associated with Th17 polarization, was de-
creased in the DSS-treated mice as compared to healthy mice (Fig. 5D).
Fig. 4. Expression of TLR2, 4, 5 and 6 within the colon. The colon was divided into proximal and distal region according the morphological characteristics described in experimental
procedures. Immunohistochemical staining was used to visualize TLR4 (A), TLR2 (B), TLR6 (C) and TLR5 (D) at both proximal and distal colon regions of either DSS-treated mice or
healthy mice. An example of a positively stained cell is indicated with an arrow in each photo. The images are representative of n = 3 mice per group.
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Although the analyzed transcription factors are generally repre-
sentative of the different T cell populations, there are also other
cells that utilize these transcription factors. To provide further infor-
mation about the underlying adaptive immune response, we per-
formed a cytokine mRNA analysis, taking into account the different
regions of the colon. We observed increased mRNA expression levels
for various pro-inﬂammatory cytokines including Tnf, Il-1beta, Ccl-2,
and Il-6 in the inﬂamed distal region of the colon from DSS-treated
mice (Fig. 6A–D). Furthermore, consistent with our transcription
factor data, the mRNA transcripts of cytokines associated with Th1
(Ifn-gamma and Il-12) were also increased at the inﬂamed distal re-
gion (Fig. 7A), whereas Th2 associated cytokines (Il-4, Il-5 and Il-13)
were clearly not up-regulated (Fig. 7C). Interestingly, although the
mRNA of the Th17 associated transcription factor, Rorc, was de-
creased in the DSS-treated mice, the Th17 associated cytokines
(Il-23 and Il-17) did show increased expression as reported in another
study (Fig. 7B) [33]. This supports the concept that DSS colitis leads to
Th1 and Th17 associated responses and also supports the relevance of
this model for CD, which also is characterized by a Th1/Th17 response
[20,33]. Finally, we also observed an increased mRNA expression of
anti-inﬂammatory cytokines (Tgf-beta and Il-10) at the inﬂamed distalregion, indicating a possible increase in activity or numbers of regulato-
ry T cells (Fig. 7D).
Since the mRNA data suggested a Th1- and Th17-associated im-
mune response during DSS colitis, we decided to measure the intra-
cellular expression of IFNγ and IL-17 in CD4+ T cells isolated from
mLN of both DSS-treated mice and healthy control mice using intra-
cellular cytokine staining. After aspeciﬁc stimulation with anti-CD3,
increased amounts of CD4+IL-17+ T cells were observed in DSS-
treated mice as compared to healthy mice (Fig. 7E). The percentage
of CD4+IFNγ+ T cells also tended to be higher in the DSS-treated
mice, though the increase was not signiﬁcant.4. Discussion
To our knowledge, this is the ﬁrst extensive survey of the mRNA
expression of PRRs along the length of the colon from both healthy
and DSS-treated mice exclusively using sensitive real-time PCR.
Though current gene array studies offer some insight into the expres-
sion of PRRs, gene arrays are not nearly as sensitive as real-time PCR
[34]. Furthermore, we have measured the transcription of PRRs along
the length of the colon. This has allowed us to observe that the major-
ity of PRRs modulate their expression in accordance with the level of
inﬂammation and damage.
Fig. 5. Colitis leads to modulations in the transcription activity of T-cell associated transcription factors. The mRNA expression of the T cell subtype-associated master transcription
factors were quantiﬁed along the colon from both DSS-treated mice and healthy mice using qPCR. Tbet (A), Gata3 (B), Foxp3 (C) and Rorc (D) are the master transcription factors
representative for Th1, Th2, Treg and Th17 cells, respectively. Results are expressed as mean ± SEM, n = 6 mice per group, pooled from two independent experiments, * p b 0.05;
** p b 0.01; *** p b 0.001.
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mRNA transcripts for the PRRs may be a result of both increased tran-
scription within resident immune cells (e.g. macrophages, mast cells
and lamina propria resident lymphocytes) and intestinal epithelial
layer cells, as well as transcriptional activity from inﬁltrating cells
(e.g. neutrophils, macrophages and T cells) [35,36]. Our immunohis-
tochemical staining showed that in the colon, TLR4 and 6 were
expressed by cells only within the epithelial layer while TLR2 was
expressed by both cells in the epithelial layer and cells within the
lamina propria. TLR5, in contrast, was only expressed by mononuclear
cells in the lamina propria. Interestingly, TLR6 was detected only in
inﬂamed distal colons mirroring the TLR6 mRNA expression data.
TLR6, which pairs with TLR2, recognizes diacylated lipopeptides [37]
and is capable of detecting Candida albicans [38]. It has been shown
that TLR6 stimulation can drive a Th17 response via the mucosal sur-
face of the lungs [39]. In a separate study, we've now found that stim-
ulation of TLR6 in the gut-associated lymphoid tissue also leads to
increased Th17 polarization (unpublished results), suggesting that
TLR6 plays a similar role at the mucosal surface of the intestines. Fur-
thermore, a TLR6 polymorphism has been reported to be associated
with the extent of IBD in the colon and, thus, Tlr6's unique expression
pattern may be indicative of strong role in initiating and/or sup-
porting inﬂammation.
The fact that TLR2−/− and TLR4−/− mice treated with DSS have a
more severe colitis than wild type mice, suggests that they may have
a protective role. However, TLR2 and TLR4 both regulate the epithelial
barrier integrity. An extensive study on TLR2 showed that deﬁciencies
of TLR2 results in early disruption of tight junction [23]. At the same
time, TLR2, as well as TLR4, are employed by a host of immune cells
to stimulate immune response. Therefore, our expression resultscannot be directly interpreted. The enhanced Tlr2 expression during
colitis may both help the barrier function repair mechanism, and, on
the other hand, encourage the immune response by stimulating the
recruitment of neutrophils [21,51] and activating dendritic cells
and macrophages [52,53]; all mechanisms to protect against bacterial
infection induced by the DSS-treatment. Ultimately, results from
TLR−/− mice should be treated with caution. Mechanisms induced
in TLR−/− mice may differ from that in wild-types, since the
knock-out mice lack TLRs from birth.
The increased expression of TLR7 and TLR9 mRNA in the colon of
DSS-treated mice might suggest the activation of IFN type 1 pathway
[54–56]. Dendritic cells express high levels of TLR7 and TLR9 and are
producers of type 1 IFN [57]. Stimulation of TLR9 and associated IFNα
production is reported to be anti-inﬂammatory in IBD [55,56]. In ad-
dition, the TLR7 ligand imiquimod induces also type 1 IFN in the in-
testinal tract of mice and reduces DSS-induced colitis [54]. Analysis
of type 1 IFN mRNA expression in inﬂamed colon of mice in this
study did not reveal an association between the enhanced expression
of TLR7 or TLR9 mRNA and IFNα mRNA, since no or very limited ex-
pression of IFNαmRNAwas detected (data not shown). The observed
increased expression of Tlr7 and Tlr9 in the inﬂamed colon could be
due to a rebound protection mechanism in DSS-colitic mice.
In the healthy colons, the expression of PRR mRNA along the colon
typically followed two patterns: the same expression along the length
of the colon or more expression at the proximal end near the caecum.
Of all the PRRs tested, only Tlr2, 3, and 5 showed a transcriptional
preference for the proximal end of the healthy colon. This may be a
consequence of increased exposure to the bacteria-rich caecum. Pre-
vious studies have shown a higher Tlr5 expression in the caecum
end of the colon [40] and Tlr2 expression is induced after exposure
Fig. 6.Modulated PRR expression is coupled with increased mRNA transcripts of pro-inﬂammatory cytokines in DSS-induced colitis. The expression of pro-inﬂammatory cytokines
Tnf (A), Ccl-2 (B), Il-1beta (C) and Il-6 (D) was examined in the four colon regions, illustrated previously. qPCR was used to quantify the mRNA expression level. Results are
expressed as mean ± SEM, n = 6 mice per group, pooled from two independent experiments, * p b 0.05; ** p b 0.01; *** p b 0,001.
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however, TLR3 typically recognizes viral RNA. Though there is little
known about the role of TLR3 in relation to the caecum, TLR3 is recog-
nized as having a special role in the detection of endogenous ligands
associated with cell necrosis via released RNA [42–44]. One could
speculate that this mechanism could be important for intestinal im-
mune homeostasis. Our observations of DSS-induced increased
mRNA expression of TLRs, except TLR5, in the distal inﬂamed colon
are in line with the report showing that DSS causes alterations of
the inner colon mucus layer that makes it permeable to bacteria
where they may trigger the epithelial cells to express higher levels
of TLRs and induce an inﬂammatory reaction [58].
Comparing control and DSS-treated mice colon, we have found
transcriptional modulation of a broad range of PRRs. Consistent with
previous studies, which compare control and IBD patient colon biop-
sies using genome-wide microarray [45,46], we have also found in-
creased mRNA levels for Nod2 and Tlr4 in the inﬂamed distal region
of colons from DSS-treated mice as compared to non-inﬂamed, con-
trol colons. In the gene array, a decreased Tlr1 expression has been
found [45,46]. Although the same decreasing was not detected, in
our study, Tlr1 is the only Tlr remains at same expression level in
both control and inﬂamed colons area. Furthermore, increased
mRNA expression of Tlrs including Tlr2 and Tlr8 were detected in
our study, which is in line with earlier reports [11,13]. A possible ex-
planation for discrepancies between the murine data and the micro-
array data in humans could be the increased sensitivity of qPCR as
compared to that with a typical microarray [34].
In our study, which included Tlr1–9 and Nod1 and 2, only the
mRNA expression of Tlr5 displayed the unique characteristic of
being down-regulated during colitis. This observation could be theresult of either the destruction of speciﬁc Tlr5 expressing cells or an
actual decrease of Tlr5 transcription activity. The former is unlikely
the case, since this would require Tlr5 to be expressed in exclusion
of other highly expressed Tlrs. Furthermore, no gross reductions of
TLR5 staining were detected in colon sections of DSS-treated mice.
Our data is in line with the study of Ortega-Cava and his colleagues,
that demonstrated a decreased intestinal TLR5 expression during
DSS colitis with the help of western blotting [47]. Interestingly, they
demonstrated that IFNγ was able to down-regulate TLR5 expression
in mice colon cells in a dose and time dependent manner [46]. Our
data showed an increased expression of Ifnγ in the colons of mice suf-
fering from colitis. This may be a possible explanation of why Tlr5 re-
ductions are observed.
Recently, UC patients were found to have lowered mucosal ex-
pression of TLR5 [48] and polymorphisms of Tlr5 in dogs were
found to be related to IBD development [40]. TLR5 is, in general, locat-
ed at the basolateral surface of intact colonic mucosa [27,49], sug-
gesting that it may have a special role during the progression of
inﬂammation. This concept is further supported by experiments ad-
ministrating the TLR5 ligand, ﬂagellin, by rectal enema in combina-
tion with DSS colitis, which have lead to aggravated disease [27] as
well as the fact that TLR5−/− mice suffer from spontaneous colitis
[50]. These data imply that TLR5 triggering is highly important during
intestinal homeostasis and the initiation of inﬂammation and its func-
tion will need to be addressed by future research.
Previous studies have shown that DSS colitis leads to the produc-
tion of Th1 and Th17 associated cytokines [16,20,59]. In line with
these data, we have also found an enhanced expression of Tbet, and
the cytokines Ifn-γ and Il-12 in the inﬂamed colon, which are associ-
ated with the differentiation of Th1 cells. In addition, the percentage
Fig. 7. Modulation of PRR expression is coupled with increased Th1/Th17 cell-associated cytokine production. The mRNA expression of T cell-associated cytokines was quantiﬁed
along the colon from both DSS treated mice and healthy mice using qPCR (A–D) and the development of Th1 and Th17 associated responses was quantiﬁed in the mLN
using ﬂuorescence-activated cell sorting (FACS) analysis (E). (A) Ifn-gamma and Il-12 are Th1 cell-associated cytokines. (C) Il-4, Il-5 and Il-13 are Th2 cell-associated cytokines.
(B) Il-23 and Il-17 are Th17 cell-associated cytokines (D) Tgf-beta and Il-10 are Treg cell-associated cytokines. (E) The percentage of CD4+IFN-γ+ cells (Th1 cells) and the percent-
age of CD4+IL-17A+ cells (Th17 cells) in cells obtained from the mLN of healthy and DSS-treated mice after CD3 stimulation. Results are expressed as mean ± SEM, n = 6 mice
per group, pooled from two independent experiments, * p b 0.05; ** p b 0.01; *** p b 0.001.
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mice undergoing DSS colitis.
Previously, an enhanced IL17A concentration was demonstrated
in colon homogenates after 6 days DSS treatment [59]. Similarly, we
also observed an increased expression of Il-23 and Il-17A in theinﬂamed colon, which are the inducer and effector cytokines of
Th17 cells, respectively. Interestingly, this ﬁnding was not correlated
with higher amounts of mRNA transcripts for the master Th17 tran-
scription factor, Rorc as we had expected. The reason for the loss of
Rorc mRNA expression in the inﬂamed colon is, at the moment, not
2171B. Zheng et al. / Biochimica et Biophysica Acta 1832 (2013) 2162–2172clear. However, it has been shown that conditions, which favor Treg,
naturally antagonize Th17 polarization [59–62]. Based on this obser-
vation, one hypothesis could be that the transcription of Rorc is
inhibited by factors, which stimulate Foxp3 expression such as perox-
isome proliferator-activated receptor (PPAR)-γ. PPAR-γ is a nuclear
receptor protein, which can be induced after stimulation of TLR sig-
naling pathway [63,64]. Activated PPAR-γ along with TGFβ encour-
ages Foxp transcription by DNA demethylation, while inhibiting Rorc
transcription [61,62]. Consistent with this idea, a study, which dem-
onstrated a TRIF and MyD88 dependent Rorc inhibition mechanism,
also showed opposing expression levels of Foxp3 and Rorc [65].
We also demonstrated an increased amount of IL-17 expression
CD4+ T cell in mLN from DSS-treated mice suggesting a speciﬁc de-
velopment antigen-speciﬁc Th17 cells that might become relevant
in a more chronic inﬂammation. The ﬁndings of Melgar and co-
workers [59] that the IL-17 production in the colon progressively in-
creased during a chronic DSS colitis model, suggests IL17 expressing T
cells may play a role in the chronic phase of colitis development.
5. Conclusion
We provide an extensive overview of the expression of Tlr1–9,
Nod1 and Nod2 in both healthy and inﬂamed colon tissue. Though,
studies in murine models of disease can never replace direct studies
within patient tissues, this work still provides valuable fundamental
information regarding PRR expression in the colon. This information
will help us, and others, to determine the precise role of different
PRRs during the development and progression of inﬂammation with-
in the colon along with providing valuable information regarding the
suitability of TLRs or NOD receptors as drug targets within IBD.
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